MedTrace Logo

Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)

NCT01025596 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-10-18

No results posted yet for this study

Summary

This study will evaluate the safety of a new experimental drug, IL-7, in people with HCV infection resistant after 12 weeks of bi-therapy.

Conditions

  • Hepatitis C

Interventions

DRUG

Interleukin-7

4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week

Sponsors & Collaborators

  • Cytheris SA

    lead INDUSTRY

Principal Investigators

  • Tilman Gerlach · University of Zurich / Saint Gallen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2011-02-28
Completion
2012-03-31

Countries

  • France
  • Italy
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01025596 on ClinicalTrials.gov